IFIT3: A Potential Drug Target and Biomarker (G3437)

Target Name: IFIT3

NCBI ID: G3437

IFIT3

IFIT3: A Potential Drug Target and Biomarker

IFIT3 (Inhibitor of Facial and Intracranial Transplantation-Induced Tissue Damage) is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the G protein family, which includes several well-known signaling molecules that play a crucial role in cellular signaling. In recent years, research has identified IFIT3 as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

IFIT3 and Cellular Signaling

IFIT3 is a G protein that is involved in several cellular signaling pathways, including the TGF-β pathway, the Wnt pathway, and theNotch pathway. The TGF-β pathway is a well-established signaling pathway that is involved in cell growth, differentiation, and repair. The Wnt pathway is a signaling pathway that is involved in the development and maintenance of tissues, including the nervous system. The Notch pathway is a signaling pathway that is involved in the regulation of cell proliferation and survival.

IFIT3 and Neurodegenerative Disorders

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic gradients. These disorders are often treated with neuroprotective agents, which aim to slow down or reverse the progression of neurodegeneration. However, the underlying mechanisms of neurodegenerative disorders are not well understood, and there is a need for new treatments that can specifically target these disorders.

IFIT3 has been identified as a potential drug target for neurodegenerative disorders due to its involvement in several signaling pathways that are involved in the development and progression of these disorders. For example, research has shown that IFIT3 is involved in the regulation of microglial cells, which are a type of immune cell that are involved in the immune response to neurodegenerative disorders. Additionally, IFIT3 has been shown to play a role in the regulation of neurotrophins, which are a type of signaling molecule that are involved in the regulation of neural circuits.

IFIT3 and Cancer

Cancer is a leading cause of death worldwide, and its development and progression are closely associated with several signaling pathways. The signaling pathways that are involved in cancer development and progression include the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. IFIT3 is involved in several of these signaling pathways, and research has shown that it can be a potential drug target for cancer.

IFIT3 has been shown to play a role in the regulation of cell proliferation and survival, as well as in the regulation of angiogenesis, which is the process by which new blood vessels are formed. Additionally, IFIT3 has been shown to play a role in the regulation of the immune response, which is a critical part of cancer defense.

IFIT3 and Autoimmune Diseases

Autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. These diseases are often treated with immunomodulatory drugs, which aim to reduce the immune system's response to the body's own tissues. IFIT3 has been identified as a potential drug target for autoimmune diseases due to its involvement in several signaling pathways that are involved in the regulation of the immune system.

IFIT3 has been shown to play a role in the regulation of T cell function, which is a critical part of the immune system. Additionally, IFIT3 has been shown to play a role in the regulation of inflammation, which is a critical part of the immune system response to injury or infection.

IFIT3 as a Potential Drug Target

IFIT3 has been shown to be a potential drug target for a variety of disorders, including neurodegenerative disorders, cancer, and autoimmune diseases. Research is ongoing to determine the most effective way to target IFIT3 and to develop new treatments for these disorders.

In

Protein Name: Interferon Induced Protein With Tetratricopeptide Repeats 3

Functions: IFN-induced antiviral protein which acts as an inhibitor of cellular as well as viral processes, cell migration, proliferation, signaling, and viral replication. Enhances MAVS-mediated host antiviral responses by serving as an adapter bridging TBK1 to MAVS which leads to the activation of TBK1 and phosphorylation of IRF3 and phosphorylated IRF3 translocates into nucleus to promote antiviral gene transcription. Exhibits an antiproliferative activity via the up-regulation of cell cycle negative regulators CDKN1A/p21 and CDKN1B/p27. Normally, CDKN1B/p27 turnover is regulated by COPS5, which binds CDKN1B/p27 in the nucleus and exports it to the cytoplasm for ubiquitin-dependent degradation. IFIT3 sequesters COPS5 in the cytoplasm, thereby increasing nuclear CDKN1B/p27 protein levels. Up-regulates CDKN1A/p21 by down-regulating MYC, a repressor of CDKN1A/p21. Can negatively regulate the apoptotic effects of IFIT2

The "IFIT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFIT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets